Hansoh Pharma and StoneWise Expand Collaboration to Accelerate AI-Driven Global Innovative Drug Discovery

China Economic Net, July 18 (Reporter Guowang Zhu) Recently, Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) and StoneWise (HK) Limited (StoneWise) announced that following their first collaboration in July 2021, the two parties have further expanded their strategic partnership in the field of AI-empowered early drug development.

According to the agreement, StoneWise will leverage its AI-powered drug molecule design platform and a multidisciplinary drug development team with extensive industry experience. By integrating multiple technical modules such as target pocket research, molecule generation, ultra-high throughput screening, and precise binding energy calculations between compounds and target proteins, StoneWise aims to enhance the efficiency and speed of early-stage new drug development while reducing costs and increasing success rates.

As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma continuously integrates superior resources under the dual-driven strategy of independent research and development and global business expansion, creating a world-class R&D system and innovation platform. With a global perspective, the company accelerates AI empowerment to explore broader and more advanced solutions for unmet clinical needs, constantly introducing promising diagnostic methods and innovative drugs.

StoneWise aims to collaborate with Hansoh Pharma to further unleash the technical capabilities of the AI platform, accelerate the deep integration of AI and the pharmaceutical industry, and jointly develop more globally competitive product pipelines, enabling high-quality medicines to benefit patients worldwide at an earlier date.